The KATE2 trial found no benefit of atezolizumab addition in the intent-to-treat population.10 The IMpassion050 trial found no increase in pCR in the intent-to-treat and PD-L1–positive populations.11 The observed discrepancy among efficacy of immunotherapy may be attributed to the difference in antitumor immunity associated with the breast cancer subtype, disease burden, or the partner regimen. Here, CD274 is linked to breast cancer.